Medical Therapy for Advanced Forms of Thyroid Cancer

Surgical Clinics of North America

Volumn 94, Issue 3, 2014, Pages 541-571

  Rajhbeharrysingh, Uma ^a   Taylor, Matthew ^a   Milas, Mira ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Advanced thyroid cancer; Anaplastic; Chemotherapy; Clinical trials; Medical therapy; Medullary and differentiated thyroid cancer; Targeted therapy

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANGIOGENESIS INHIBITOR; AXITINIB; BORTEZOMIB; CABOZANTINIB; COMBRETASTATIN; COMBRETASTATIN A4 PHOSPHATE; DABRAFENIB; DNA METHYLTRANSFERASE INHIBITOR; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MOTESANIB; MULTIKINASE INHIBITOR; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; ROMIDEPSIN; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; XL 281;

ABLATION THERAPY; ADVANCED CANCER; ALGORITHM; ANAPLASTIC THYROID CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE PREDISPOSITION; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID METASTASIS; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADVANCED THYROID CANCER; ANAPLASTIC; CHEMOTHERAPY; CLINICAL TRIALS; MEDICAL THERAPY; MEDULLARY AND DIFFERENTIATED THYROID CANCER; TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84901197507     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.03.003     Document Type: Review

References (108)

1. Howlader N., Noone A.M., Krapcho M., et al. SEER cancer statistics review, 1975-2010 2013, National Cancer Institute, Bethesda (MD), Available at:, based on November 2012 SEER data submission. Posted to the SEER Web site, 2013. http://seer.cancer.gov/csr/1975_2010/.
2. Carhill A.A., Cabanillas M.E., Jimenez C., et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. JClin Endocrinol Metab 2013, 98(1):31-42.
3. Cabanillas M.E., Waguespack S.G., Bronstein Y., et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. JClin Endocrinol Metab 2010, 95(6):2588-2595.
4. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. JClin Endocrinol Metab 2006, 91(8):2892-2899.
5. Sherman S.I. Targeted therapy of thyroid cancer. Biochem Pharmacol 2010, 80(5):592-601.
6. Leeper R.D., Shimaoka K. Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 1980, 9(2):383-404.
7. Gild M.L., Bullock M., Robinson B.G., et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011, 7:617-624.
8. Haugen B.R., Sherman S.I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013, 34(3):439-455.
9. Couto P.J., Prazeres H., Castro P., et al. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. JClin Pathol 2009, 62(5):414-421.
10. Giuffrida D., Prestifilippo A., Scarfia A., et al. New treatment in advanced thyroid cancer. JOncol 2012, 2012:391629.
11. Chang Y.S., Lin I.L., Yeh K.T., et al. Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension. Clin Biochem 2013, 46(15):1572-1577.
12. Elisei R., Viola D., Torregrossa L., et al. The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. JClin Endocrinol Metab 2012, 97(12):4390-4398.
13. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. JClin Oncol 2008, 26(29):4708-4713.
14. Cabanillas M.E., Hu M.I., Durand J.B., et al. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. JThyroid Res 2011, 2011:985780.
15. DECISION trial Nexavar® versus placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer. Available at:. http://clinicaltrials.gov.
16. Brose M.S., Nutting C., Jarzab B. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. JClin Oncol 2013, 31S(4).
17. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer. Available at:. http://clinicaltrials.gov.
18. Sherman S.I., Jarzab B., Cabanillas M.E., et al. Aphase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). JClin Oncol 2011, 29(15S):5503.
19. Fallahi P., Ferrari S.M., Santini F., et al. Sorafenib and thyroid cancer. BioDrugs 2013, 27(6):615-628.
20. Harvey R.D., Owonikoko T.K., Lewis C.M., et al. Aphase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. Br J Cancer 2013, 108(4):762-765.
21. Putzer D., Gabriel M., Kroiss A., et al. First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin Nucl Med 2012, 37(6):539-544.
22. Kapiteijn E., Schneider T.C., Morreau H., et al. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012, 23(1):10-18.
23. Argiris A., Agarwala S.S., Karamouzis M.V., et al. Aphase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008, 26(2):183-188.
24. Jin J., Phitayakorn R., Wilhelm S.M., et al. Advances in management of thyroid cancer. Curr Probl Surg 2013, 50(6):241-289.
25. Grabowski P., Briest F., Baum R.P., et al. Vandetanib therapy in medullary thyroid cancer. Drugs Today (Barc) 2012, 48(11):723-733.
26. Almeida M.Q., Hoff A.O. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 2012, 24(3):229-234.
27. Antonelli A., Bocci G., La Motta C., et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity invitro and invivo in papillary dedifferentiated thyroid cancer. JClin Endocrinol Metab 2011, 96(2):E288-E296.
28. Ciampi R., Romei C., Cosci B., et al. Chromosome 10 and RET gene copy number alterations in hereditary and sporadic medullary thyroid carcinoma. Mol Cell Endocrinol 2012, 348(1):176-182.
29. Couto J.P., Almeida A., Daly L., et al. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. PLoS One 2012, 7(10):e46869.
30. Campbell M.J., Seib C.D., Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer. Curr Opin Oncol 2013, 25(1):39-43.
31. Bible K.C., Suman V.J., Menefee M.E., et al. Amulti-institutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. JClin Endocrinol Metab 2012, 97(9):3179-3184.
32. Granata R., Locati L., Licitra L. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Curr Opin Oncol 2013, 25(3):224-228.
33. Kebebew E. Anaplastic thyroid cancer: rare, fatal, and neglected. Surgery 2012, 152(6):1088-1089.
34. Wein R.O., Weber R.S. Anaplastic thyroid carcinoma: palliation or treatment?. Curr Opin Otolaryngol Head Neck Surg 2011, 19(2):113-118.
35. Deshpande H.A., Roman S., Sosa J.A. New targeted therapies and other advances in the management of anaplastic thyroid cancer. Curr Opin Oncol 2013, 25(1):44-49.
36. Chan C.M., Jing X., Pike L.A., et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res 2012, 18(13):3580-3591.
37. De Falco V., Buonocore P., Muthu M., et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. JClin Endocrinol Metab 2013, 98(5):E811-E819.
38. Wunderlich A., Roth S., Ramaswamy A., et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine 2012, 42(3):637-646.
39. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper D.S., Doherty G.M., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-1214.
40. National Cancer Institute - Clinical trials for treatment of thyroid cancer. Available at:. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12047419.
41. Schlumberger M., Massicotte M.H., Nascimento C.L., et al. Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics (Sao Paulo) 2012, 67(Suppl 1):125-129.
42. American Thyroid Association Guidelines Task Force, Kloos R.T., Eng C., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19(6):565-612.
43. Smallridge R.C., Ain K.B., Asa S.L., et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012, 22(11):1104-1139.
44. O'Neill J.P., Shaha A.R. Anaplastic thyroid cancer. Oral Oncol 2013, 49(7):702-706.
45. National Cancer Institute - palliative chemotherapy. Available at:. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page7.
46. Dabrafenib with or without trametinib in treating patients with recurrent thyroid cancer. Available at:. http://clinicaltrials.gov.
47. Everolimus in treating patients with progressive or recurrent, unresectable, or metastatic thyroid cancer. Available at:. http://clinicaltrials.gov.
48. Everolimus in treating patients with locally advanced or metastatic thyroid cancer. Available at:. http://clinicaltrials.gov.
49. A trial of pasireotide and everolimus in adult patients with radioiodine-refractory differentiated and medullary thyroid cancer. Available at:. http://clinicaltrials.gov.
50. Study of everolimus and sorafenib in patients with advanced thyroid cancer who progressed on sorafenib alone. Available at:. http://clinicaltrials.gov.
51. Pennell N.A., Daniels G.H., Haddad R.I., et al. Aphase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18(3):317-323.
52. Ho A.L., Grewal R.K., Leboeuf R., et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. NEngl J Med 2013, 368(7):623-632.
53. Combination of temsirolimus and sorafenib in the treatment of radioactive iodine refractory thyroid cancer. Available at:. http://clinicaltrials.gov.
54. Hong D.S., Cabanillas M.E., Wheler J., et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. JClin Endocrinol Metab 2011, 96(4):997-1005.
55. Kim K.B., Cabanillas M.E., Lazar A.J., et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF (V600E) mutation. Thyroid 2013, 23(10):1277-1283.
56. A study of RO5185426 (vemurafenib) in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF V600 mutation. Available at:. http://clinicaltrials.gov.
57. Study of XL281 in adults with solid tumors. Available at:. http://clinicaltrials.gov.
58. Rosen L.S., Kurzrock R., Mulay M., et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. JClin Oncol 2007, 25(17):2369-2376.
59. Sherman S.I., Wirth L.J., Droz J.M., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. NEngl J Med 2008, 359(1):31-42.
60. Bible K.C., Suman V.J., Molina J.R., et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11(10):962-972.
61. Pazopanib hydrochloride in treating patients with advanced thyroid cancer. Available at:. http://clinicaltrials.gov.
62. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. JClin Oncol 2008, 26(29):4714-4719.
63. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. JClin Oncol 2009, 27(10):1675-1684.
64. Hoftijzer H., Heemstra K.A., Morreau H., et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009, 161(6):923-931.
65. Nexavar® versus placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer. Available at:. http://clinicaltrials.gov.
66. Ahmed M., Barbachano Y., Riddell A., et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011, 165(2):315-322.
67. Capdevila J., Iglesias L., Halperin I., et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012, 19(2):209-216.
68. Schneider T.C., Abdulrahman R.M., Corssmit E.P., et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012, 167(5):643-650.
69. Cohen B.M., Needles K.J., Cullen S.J., et al. Phase 2 study of sunitinib in refractory thyroid cancer. JClin Oncol 2008, 28(15):6025.
70. Goulart B., Carr L., Martins R.G., et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). JClin Oncol 2008, 26(15):6062.
71. Ravaud A., de la Fouchardiere C., Asselineau J., et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010, 15(2):212-213. [author reply: 214].
72. Carr L.L., Mankoff D.A., Goulart B.H., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16(21):5260-5268.
73. Leboulleux S., Bastholt L., Krause T., et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012, 13(9):897-905.
74. Bortezomib in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy. Available at:. http://clinicaltrials.gov.
75. Cediranib maleate with or without lenalidomide in treating patients with thyroid cancer. Available at:. http://clinicaltrials.gov.
76. Ain K.B., Lee C., Williams K.D. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007, 17(7):663-670.
77. Thalidomide in treating patients with thyroid cancer. Available at:. http://clinicaltrials.gov.
78. Mrozek E., Kloos R.T., Ringel M.D., et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. JClin Endocrinol Metab 2006, 91(6):2201-2204.
79. Piekarz R., Luchenko L., Draper D., et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. JClin Oncol 2008, 26(15S):3571.
80. Amiri-Kordestani L., Luchenko V., Peer C.J., et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res 2013, 19(16):4499-4507.
81. Sherman E.J., Su Y.B., Lyall A., et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid 2013, 23(5):593-599.
82. Romidepsin in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine. Available at:. http://clinicaltrials.gov.
83. A phase II trial of valproic acid in patients with advanced thyroid cancers of follicular cell origin. Available at:. http://clinicaltrials.gov.
84. Woyach J.A., Kloos R.T., Ringel M.D., et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. JClin Endocrinol Metab 2009, 94(1):164-170.
85. Azacitidine to restore thyroid function in patients with persistent or metastatic thyroid cancer. Available at:. http://clinicaltrials.gov.
86. Decitabine in treating patients with metastatic papillary thyroid cancer or follicular thyroid cancer unresponsive to iodine I 131. Available at:. http://clinicaltrials.gov.
87. SOM230 alone or in combination with RAD001 in patients with medullary thyroid cancer. Available at:. http://clinicaltrials.gov.
88. Kurzrock R., Sherman S.I., Ball D.W., et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. JClin Oncol 2011, 29(19):2660-2666.
89. Schoffski P., Elisei R., Muller S., et al. An international, double-blind, randomized, placebo-controlled Phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. JClin Oncol 2012, 30S:5508.
90. Frank-Raue K., Fabel M., Delorme S., et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007, 157(2):215-220.
91. Imatinib in combination with dacarbazine and capecitabine in medullary thyroid carcinoma. Available at:. http://clinicaltrials.gov.
92. Schlumberger M. Aphase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). JClin Oncol 2012, 30S. [abstract: 5591].
93. Schlumberger M.J., Elisei R., Bastholt L., et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. JClin Oncol 2009, 27(23):3794-3801.
94. Ponatinib for advanced medullary thyroid cancer. Available at:. http://clinicaltrials.gov.
95. Lam E.T., Ringel M.D., Kloos R.T., et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. JClin Oncol 2010, 28(14):2323-2330.
96. Sorafenib tosylate in treating patients with metastatic, locally advanced, or recurrent medullary thyroid cancer. Available at:. http://clinicaltrials.gov.
97. Robinson B.G., Paz-Ares L., Krebs A., et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. JClin Endocrinol Metab 2010, 95(6):2664-2671.
98. Wells S.A., Robinson B.G., Gagel R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. JClin Oncol 2012, 30(2):134-141.
99. To compare the effects of two doses of vandetanib in patients with advanced medullary thyroid cancer. Available at:. http://clinicaltrials.gov.
100. Ha H.T., Lee J.S., Urba S., et al. Aphase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010, 20(9):975-980.
101. Savvides P., Nagaiah G., Lavertu P., et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2013, 23(5):600-604.
102. Nagaiah G., Fu P., Wasman J.K., et al. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). JClin Oncol 2009, 27(Suppl 15). [abstract 6058].
103. Combretastatin A4 phosphate in treating patients with advanced anaplastic thyroid cancer. Available at:. http://clinicaltrials.gov.
104. Cooney M.M., Savvides P., Agarwala S. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). JClin Oncol 2006, 24(18S):5580.
105. A phase i/ii trial of crolibulin (EPC2407) plus cisplatin in adults with solid tumors with a focus on anaplastic thyroid cancer (ATC). Available at:. http://clinicaltrials.gov.
106. Mooney C.J., Nagaiah G., Fu P., et al. Aphase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009, 19(3):233-240.
107. Fosbretabulin or placebo in combination with carboplatin/paclitaxel in anaplastic thyroid cancer (FACT2). Available at:. http://clinicaltrials.gov.
108. Sosa J.A., Elisei R., Jarzab B., et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 2014, 24(2):232-240.